{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:54:55Z","timestamp":1778864095675,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment with clozapine requires regular blood monitoring in order to minimise the risk of agranulocytosis. The demands on patients and clinicians associated with monitoring may be reduced by using point-of-care, as opposed to lab-based assessments. We assessed the utility of a device that can measure white blood cell (WBC) and neutrophil counts by capillary fingerstick blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>The performance of a small, portable device (HemoCue\u00ae WBC DIFF System) was compared with that of a widely used laboratory analyser (ADVIA\u00ae 2120i) for measuring WBC and neutrophil counts. Patients with schizophrenia who were being treated with clozapine ( n\u2009=\u2009201) provided a fingerstick capillary sample and a venous sample for the respective assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      WBC counts and neutrophil counts from venous blood as determined by ADVIA 2120i, ranged from 3.0\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l to 19.5\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l, and 1.2\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l to 15.9\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l, respectively. There was a strong correlation between the results from venous and the capillary sample methods (WBC: R\u2009=\u20090.89, neutrophil: R\u2009=\u20090.92). By Passing\u2013Bablok regression analysis, the slope of the association between ADVIA\n                      <jats:sup>\u00ae<\/jats:sup>\n                      2120i and HemoCue WBC DIFF for WBC was 1.0 [95% confidence interval (CI) 0.944\u20131.086], with intercept at \u22120.9 (95% CI \u22121.43 to \u22120.45). For neutrophils, the slope was 0.870 (95% CI 0.817\u20130.923), with intercept at \u22120.19 (95% CI \u22120.43 to 0.02). Overall, mean biases of \u22120.95\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l for WBC, and \u22120.91\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l for neutrophils were observed for the capillary blood method compared with the venous blood method. Below the clinical cutoff intervals for clozapine monitoring WBC (&lt;3.5\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l) and neutrophils (&lt;1.5\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l) these biases were \u22121.1\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l for WBC, and \u22120.25\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/l for neutrophils.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results from the capillary blood HemoCue WBC DIFF analyser compared well with the venous blood ADVIA 2120i analyser for determining WBC and neutrophil counts. There was a slight overall bias, with the capillary method reporting lower values for both measures. Fingerstick point-of-care analysis is suitable for monitoring blood counts in patients on clozapine, although confirmatory standard venous testing is recommended for test results falling below accepted thresholds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253211000865","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T05:36:54Z","timestamp":1616650614000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Using a fingerstick test for haematological monitoring in patients treated with clozapine"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-8343","authenticated-orcid":false,"given":"Matthew","family":"Atkins","sequence":"first","affiliation":[{"name":"Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK"},{"name":"Institute of Pharmaceutical Science, Kings College, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"McGuire","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry , King\u2019s College, London, UK"},{"name":"National Institute of Health Research Biomedical Research Centre at SLaM NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhirundra","family":"Balgobin","sequence":"additional","affiliation":[{"name":"Clozapine Clinic, South London and Maudsley NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravinkumar","family":"Patel","sequence":"additional","affiliation":[{"name":"Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-1710","authenticated-orcid":false,"given":"David","family":"Taylor","sequence":"additional","affiliation":[{"name":"Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK"},{"name":"Institute of Pharmaceutical Science, Kings College, London"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"bibr1-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08030368"},{"key":"bibr2-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16121358"},{"key":"bibr3-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719000369"},{"key":"bibr4-20451253211000865","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor D","year":"2019","edition":"13"},{"key":"bibr5-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12193"},{"key":"bibr6-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000188"},{"key":"bibr7-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1111\/apa.13790"},{"key":"bibr8-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.11.022"},{"key":"bibr9-20451253211000865","first-page":"709","volume":"21","author":"Passing H and Bablok","year":"1983","journal-title":"J Clin Chem Clin Biochem"},{"key":"bibr10-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12561"},{"key":"bibr11-20451253211000865","unstructured":"Zaponex. Zaponex (clozapine) abbreviated prescribing information, https:\/\/www.zaponex.co.uk\/tablet-prescribing-information (2018, accessed 15 September 2020)."},{"key":"bibr12-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2008.01093.x"},{"key":"bibr13-20451253211000865","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666180807094654"},{"key":"bibr14-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A417"},{"key":"bibr15-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1476"},{"key":"bibr16-20451253211000865","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2018-0188"},{"key":"bibr17-20451253211000865","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.KEBE.070415"},{"key":"bibr18-20451253211000865","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.05.046"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253211000865","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253211000865","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253211000865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:52:18Z","timestamp":1777593138000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253211000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":18,"alternative-id":["10.1177\/20451253211000865"],"URL":"https:\/\/doi.org\/10.1177\/20451253211000865","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"20451253211000865"}}